Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Hopes of a blockbuster for Celgene's (CELG) apremalist fade after Phase III results showed just 33% of patients had a 75% reduction in psoriasis vs. 41% in the midstage trial. Management had hoped for $1.1B-$1.75B in peak sales for the drug, a figure few on the Street were buying. (PR[View news story]
    For all those who think the results are disappointing (Wall St Journal, others, etc) they really don't understand medicine. There was no 40% consensus. Consensus is for earnings estimates, not clinical trials. Comparing a phase II and phase III trial is very difficult to do. The numbers in phase II are always substantially less than phase III. Plus most phase II trials do not show comparable efficacy when larger phase III trials are done. These results are very good, especially in a disease whose front line drugs are far more toxic (methotrexate and Embrel). Side effect profile was essentially no different than placebo. Also oral administration vs subcutaneous injection is preferable. Not to mention nearly a third of patients had already seen previous biologic therapy.
    Mar 4, 2013. 07:47 AM | Likes Like |Link to Comment
1 Comment